|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CXorf23 |
Gene summary for CXORF23 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CXorf23 | Gene ID | 256643 |
| Gene name | BCLAF1 and THRAP3 family member 3 | |
| Gene Alias | CXorf23 | |
| Cytomap | Xp22.12 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A2AJT9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 256643 | CXorf23 | HCC1_Meng | Human | Liver | HCC | 9.64e-18 | -1.42e-03 | 0.0246 |
| 256643 | CXorf23 | HCC2_Meng | Human | Liver | HCC | 2.31e-20 | 1.44e-01 | 0.0107 |
| 256643 | CXorf23 | HCC1 | Human | Liver | HCC | 1.46e-03 | 1.62e+00 | 0.5336 |
| 256643 | CXorf23 | HCC2 | Human | Liver | HCC | 5.13e-21 | 3.24e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CXorf23 | SNV | Missense_Mutation | c.536T>C | p.Ile179Thr | p.I179T | A2AJT9 | protein_coding | tolerated(0.25) | benign(0.013) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| CXorf23 | SNV | Missense_Mutation | novel | c.21N>T | p.Arg7Ser | p.R7S | A2AJT9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A576-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| CXorf23 | insertion | Frame_Shift_Ins | novel | c.1456_1457insGCTTTCCGAACCTGCTC | p.Tyr486CysfsTer30 | p.Y486Cfs*30 | A2AJT9 | protein_coding | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | ||
| CXorf23 | insertion | Nonsense_Mutation | novel | c.1042_1043insGTAGAGGAGATTATACCATAATCTGGGAAGATACCTATTTATA | p.Asp348GlyfsTer15 | p.D348Gfs*15 | A2AJT9 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| CXorf23 | SNV | Missense_Mutation | c.1935N>C | p.Gln645His | p.Q645H | A2AJT9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| CXorf23 | SNV | Missense_Mutation | novel | c.1369N>A | p.Leu457Ile | p.L457I | A2AJT9 | protein_coding | tolerated(0.06) | possibly_damaging(0.814) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CXorf23 | SNV | Missense_Mutation | c.1351C>T | p.His451Tyr | p.H451Y | A2AJT9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CXorf23 | insertion | In_Frame_Ins | novel | c.977_978insGTTGGT | p.Asn326delinsLysLeuVal | p.N326delinsKLV | A2AJT9 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| CXorf23 | SNV | Missense_Mutation | c.1795G>T | p.Asp599Tyr | p.D599Y | A2AJT9 | protein_coding | tolerated(0.13) | possibly_damaging(0.875) | TCGA-AA-3696-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| CXorf23 | SNV | Missense_Mutation | rs751543626 | c.143N>T | p.Ala48Val | p.A48V | A2AJT9 | protein_coding | tolerated(0.28) | benign(0.023) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |